NasdaqGS - Nasdaq Real Time Price USD

Royalty Pharma plc (RPRX)

67.18 +1.25 (+1.90%)

At close: October 30 at 4:00:00 PM EDT

67.60 +0.42 (+0.63%)

After hours: October 30 at 5:13:47 PM EDT

Trade RPRX on Coinbase

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for RPRX

Previous Close 65.93
Open 67.00
Bid 61.60 x 200
Ask 72.51 x 200
Day's Range 66.40 - 67.71
52 Week Range 36.03 - 67.71
Volume 4,660,607
Avg. Volume 3,079,496
Market Cap (intraday) 38.819B
Beta (5Y Monthly) 0.41
PE Ratio (TTM) 35.73
EPS (TTM) 1.88
Earnings Date Nov 4, 2026
Forward Dividend & Yield 0.94 (1.40%)
1y Target Est 65.38
Morningstar Rating Rating available with Stock Picks access

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

www.royaltypharma.com

100

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

RPRX

76.25%

S&P 500 (^GSPC)

10.73%

1-Year Return

RPRX

85.39%

S&P 500 (^GSPC)

11.11%

3-Year Return

RPRX

171.63%

S&P 500 (^GSPC)

81.91%

5-Year Return

RPRX

91.01%

S&P 500 (^GSPC)

64.59%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q2 FY26

Revenue 773M

Earnings 17.88M

Profit Margin 2.31%

FY25

FY26

200M

400M

600M

800M

0.0%

10.0%

20.0%

30.0%

Analyst Price Targets

61.00 Low

65.38 Average

67.18 Current

70.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 10/7/2026

Analyst Morgan Stanley

Rating Action Maintains

Rating Overweight

Price Action Raises

Price Target 65 -> 67

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

32.02%
Return on Assets (ttm)

5.09%
Return on Equity (ttm)

13.97%
Revenue (ttm)

2.54B
Net Income Avi to Common (ttm)

811.99M
Diluted EPS (ttm)

1.88

Balance Sheet and Cash Flow

Total Cash (mrq)

836.99M
Total Debt/Equity (mrq)

91.58%
Levered Free Cash Flow (ttm)

-1.2B

GTM ZoomInfo Technologies Inc.

4.3600 -2.68%

NCNO nCino, Inc.

22.68 +1.02%

CYTK Cytokinetics, Incorporated

62.99 -0.51%

ALNY Alnylam Pharmaceuticals, Inc.

165.00 -5.17%

GDRX GoodRx Holdings, Inc.

3.4900 -1.41%

U.S. markets closed

Royalty Pharma plc (RPRX)

Trading disclosure

5.20%

15.11%

34.12%

73.86%

81.86%

69.95%

52.68%

Royalty Pharma plc Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch